IDEAS home Printed from https://ideas.repec.org/a/taf/regstd/v44y2010i8p1053-1066.html
   My bibliography  Save this article

The Evolution of Firm Growth Dynamics in the US Pharmaceutical Industry

Author

Listed:
  • Pelin Demirel
  • Mariana Mazzucato

Abstract

Demirel P. and Mazzucato M. The evolution of firm growth dynamics in the US pharmaceutical industry, Regional Studies. This paper studies the dynamics of firm growth and firm size distribution in the pharmaceutical industry from 1950 to 2003. Growth dynamics are studied in the context of how the size composition of firms changes, how innovation patterns change, and how location leads to growth differentials among US firms. It is found that the growth advantage of small pharmaceutical firms increases after the 1980s as small firms become more active in patenting and their patenting activities become more 'persistent'. Location is found to affect growth differences only for the most innovative firms (that is, for non-innovative firms, location does not matter). [image omitted] Demirel P. et Mazzucato M. L'evolution de la dynamique de la croissance des entreprises dans l'industrie pharmaceutique aux Etats-Unis, Regional Studies. Cet article cherche a etudier la dynamique de la croissance des entreprises et de la distribution des entreprises par taille dans l'industrie pharmaceutique de 1950 jusqu'a 2003. On etudie la dynamique de la croissance pour determiner comment la distribution des entreprises par taille evolue, comment la structure de l'innovation change, et comment la localisation entraine des ecarts de la croissance des entreprises aux Etats-Unis. Il s'avere que l'avantage des petites entreprises pharmaceutiques en termes de croissance augmente apres les annees 1980 au fur et a mesure que les petites entreprises obtiennent davantage de brevets et que le brevetage 'persiste'. Il s'avere que la localisation n'influe sur les ecarts de croissance que pour les entreprises les plus innovatrices (c'est a dire que la localisation n'importe pas pour les entreprises qui ne sont pas innovatrices). Croissance des entreprises Innovation Industrie pharmaceutique Demirel P. und Mazzucato M. Die Evolution der Wachstumsdynamik von Firmen in der pharmazeutischen Industrie der USA, Regional Studies. In diesem Beitrag untersuchen wir die Dynamik von Firmenwachstum und Firmengrossenverteilung in der pharmazeutischen Industrie im Zeitraum von 1950 bis 2003. Die Wachstumsdynamik wird im Kontext der Frage untersucht, wie sich die Grossenzusammensetzung der Firmen andert, wie sich die Innovationsablaufe andern und wie der Standort zu Wachstumsdifferentialen zwischen Firmen in den USA fuhrt. Wir stellen fest, dass der Wachstumsvorteil kleiner pharmazeutischer Firmen nach den achtziger Jahren zunimmt, da die kleineren Firmen bei der Patentierung aktiver und ihre Patentierungsaktivitaten bestandiger werden. Der Standort wirkt sich hingegen nur bei den innovativsten Firmen auf Wachstumsdifferenzen aus (mit anderen Worten, bei nicht innovativen Firmen kommt es nicht auf den Standort an). Firmenwachstum Innovation Pharmaindustrie Demirel P. y Mazzucato M. La evolucion de las dinamicas de crecimiento de empresas en la industria farmaceutica de los Estados Unidos, Regional Studies. En este articulo analizamos las dinamicas del crecimiento de empresas y la distribucion del tamano de las empresas en la industria farmaceutica de 1950 a 2003. Estudiamos las dinamicas de crecimiento en cuanto a como cambia la composicion del tamano de las empresas, como cambian los modelos de innovacion y como lleva la ubicacion a diferenciales de crecimiento entre empresas estadounidenses. Observamos que la ventaja de crecimiento de pequenos laboratorios farmaceuticos aumenta despues de la decada de los ochenta cuando las pequenas empresas se vuelven mas activas con las patentes y las actividades relacionadas con patentes son mas 'persistentes'. Vemos que la ubicacion afecta a las diferencias de crecimiento solamente en empresas mas innovadoras (es decir, para las empresas no tan innovadoras la ubicacion no importa). Crecimiento de empresas Innovacion Industria farmaceutica

Suggested Citation

  • Pelin Demirel & Mariana Mazzucato, 2010. "The Evolution of Firm Growth Dynamics in the US Pharmaceutical Industry," Regional Studies, Taylor & Francis Journals, vol. 44(8), pages 1053-1066.
  • Handle: RePEc:taf:regstd:v:44:y:2010:i:8:p:1053-1066
    DOI: 10.1080/00343400903241469
    as

    Download full text from publisher

    File URL: http://www.tandfonline.com/doi/abs/10.1080/00343400903241469
    Download Restriction: Access to full text is restricted to subscribers.

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Giovanni Dosi, 2008. "Statistical Regularities in the Evolution of Industries. A Guide through Some Evidence and Challenges for the Theory," L'industria, Società editrice il Mulino, issue 2, pages 185-220.
    2. Francesca Lotti & Enrico Santarelli & Marco Vivarelli, 2009. "Defending Gibrat’s Law as a long-run regularity," Small Business Economics, Springer, vol. 32(1), pages 31-44, January.
    3. Giulio Bottazzi & Elena Cefis & Giovanni Dosi & Angelo Secchi, 2003. "Invariances and Diversities in the Evolution of Manufacturing Industries," LEM Papers Series 2003/21, Laboratory of Economics and Management (LEM), Sant'Anna School of Advanced Studies, Pisa, Italy.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Jean Dubé & Cédric Brunelle, 2014. "Dots to dots: a general methodology to build local indicators using spatial micro-data," The Annals of Regional Science, Springer;Western Regional Science Association, vol. 53(1), pages 245-272, August.
    2. repec:kap:jbuset:v:146:y:2017:i:1:d:10.1007_s10551-015-2959-8 is not listed on IDEAS
    3. Rachel Bocquet & Christian Le Bas & Caroline Mothe & Nicolas Poussing, 2017. "CSR, Innovation, and Firm Performance in Sluggish Growth Contexts: A Firm-Level Empirical Analysis," Journal of Business Ethics, Springer, vol. 146(1), pages 241-254, November.

    More about this item

    Keywords

    Firm growth; Innovation; Pharmaceutical industry;

    Lists

    This item is featured on the following reading lists or Wikipedia pages:
    1. Usuario:Violetaguitart/Taller in Wikipedia Spanish ne '')

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:taf:regstd:v:44:y:2010:i:8:p:1053-1066. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Chris Longhurst). General contact details of provider: http://www.tandfonline.com/CRES20 .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.